KRAS and lung carcinoma: Lung cancer cells with KRAS/MYC cooperation exhibited more pronounced proliferation and aggressiveness, as well as suppressive and inflammatory features of the immune microenvironment, compared to KRASG12D mutations alone [69, 70].